Novo Nordisk’s stock dropped by 15% on Monday after news that its weight-loss drug, CagriSema, did not meet its main goal. The drug failed to show it was as effective as Eli Lilly’s competitor, tirzepatide. This is disappointing for Novo, especially since tirzepatide has already gained significant traction with popular medications like Mounjaro and Zepbound.
Novo Nordisk reported that patients taking a 2.4 mg dose of CagriSema lost 23% of their weight after 84 weeks, but this was lower than the 25.5% weight loss achieved with a 15 mg dose of tirzepatide. As a result, Novo’s shares fell to 256 Danish kroner, marking their lowest point since June 2021. Meanwhile, Eli Lilly’s stock rose by 3.5% in premarket trading.
This setback is not just a minor bump; it’s part of a larger trend facing Novo. Earlier this month, the company warned that its sales and profit could decrease by 5% to 13% in 2026 due to rising competition and price drops in the U.S. market. Novo’s CEO, Mike Doustdar, cautioned investors to be prepared for further declines before any potential recovery.
Novo is not giving up on CagriSema just yet. The company is looking into further trials, possibly with higher doses. Chief Scientific Officer Martin Holst Lange remains optimistic about the drug’s potential. He believes that CagriSema could be the first product combining GLP-1 and amylin therapies designed to treat obesity effectively.
Investor sentiment is crucial during times like this. Some analysts believe that while setbacks like these can hurt in the short term, the long-term potential for innovative treatments like CagriSema could turn things around if the additional trials pan out.
For those interested in the weight-loss drug market, this situation reflects the ongoing battle between pharmaceutical companies that have developed groundbreaking treatments. A recent survey from IQVIA found that the prescription market for obesity medications is expected to grow significantly, particularly as more options emerge.
In conclusion, while Monday’s news was tough for Novo Nordisk, it also highlights the fierce competition in the diabetes and obesity treatment landscape. The outcome of further trials will be critical—not just for Novo but for the many patients relying on effective weight-loss therapies.
Source link
Breaking news,Pharmaceuticals,Novo Nordisk A/S,iShares Genomics Immunology and Healthcare ETF,Eli Lilly and Co,iShares MSCI Denmark ETF,Spdr S&P Pharmaceuticals Etf,iShares U.S. Pharmaceuticals ETF,Novo Nordisk A/S,Biotech and Pharmaceuticals,Health care industry,Breaking News: Europe,business news
